Cancer is Still a Major Problem

•

0 likes•232 views

While cancer death rates have declined for some cancers, cancer remains a major public health problem, causing over 600,000 deaths per year in the US alone. Recent progress includes better understanding of cancer at the molecular level, leading to more targeted and personalized therapies. However, fewer patients enroll in clinical trials and many drug candidates fail in late-stage trials due to challenges including a lack of predictive animal models and the high cost of large trials. There is pressure to find cheaper and earlier answers on drug efficacy through biomarkers and trial design innovations to improve the challenging process of bringing new cancer treatments to patients.

Health & Medicine Business

Cancer Still a Major Problem
• 600,000 deaths per year in US
• 1,500 per day

Progress has been made
• People living longer with cancer
• Five year survival overall is 67%
• Better understanding of the science of
cancer has led to better diagnosis and
treatment

Death rates declining for some
tumors
• Prostate
• Breast
• Lung
• Colorectal

Death rates rising for others
• Pancreas
• Liver

New ways of thinking about
cancer
Old
by site and type of tissue ie
adenocarcinoma of the lung
New
by cellular abnormality ie EGRF mutation

Understanding pathways and
interactions
• Leading to targeted therapies
• Companion diagnostics
• Better understanding of resistance
mechanisms
• Combination approaches

New understanding of factors
external to tumor
• Tumor vasculature and stromal cells
• Immune tolerance

Able to target specific
abnormalities
• More individualized approach
• Companion diagnostics to screen patients
likely to respond
• Better understanding of resistance
mechanisms

Many drugs in trials
• More than a thousand cancer trials
• 47 new cancer drugs approved in last 10
years

Few patients enter trials
• Less than 5% of eligible patients

Many trials /drugs fail
• 5% of drugs that enter trials are approved
• 60% of successful Phase II drugs fail in
Phase III

Causes of trial failure
• Too few patients
• Poor choice of endpoint

Health economics
• Need for differentiation/advantage
• Puts pressure on companies to do larger
more expensive trials

Biotech engine for inovation
• Pharma pipeline cannot keep up with
demand

Biotech model broken
• Over last 10 years 0.8X return to investors

Less money available to
startups
• VC’s more cautious
• Less money invested in biotech

Significant problem for oncology
drugs
Traditionally poor prediction from
animal models
some improvement with
knockout models and patient derived
samples
Trials long and expensive

Pressure for early less expensive
answers
• Biomarkers
• Clever trial design
• Patient enrichment
• Need for “Phase III results from Phase I trial”

Opportunity for Ockham
• Partner of choice to derisk programs early

At the Seventh Annual Health Law Year in P/Review symposium, leading experts discussed major developments during 2018 and what to watch out for in 2019. Speakers covered hot topics including health policy under the current administration, pharmaceutical policy, and public health law. Featured panels explored "Challenges Facing Health Care General Counsels" and "AI in Health Care." For more, go to: http://petrieflom.law.harvard.edu/events/details/seventh-annual-health-law-year-in-p-review

The Future of Value-Based Care (Harlan Levine)

U.S. News Healthcare of Tomorrow

Standard of Care - Donna BeardsworthTTC, llc

Status Quo of Genomics Industry

Yasin Memari

Revolutionizing Renal Care With Predictive Analytics for CKD

Viewics

Chronic Kidney Disease (CKD) is a common and growing condition, affecting about half of the Medicare population and of diabetics. In the United States, the lifetime risk of CKD for 30-year-olds is now greater than half, and the prevalence of CKD is projected to rise significantly over the next 15 years. Current methods of predicting which CKD patients will progress to renal failure and require dialysis or transplant have low accuracy rates, causing great anxiety and suboptimal care. Without accurate risk prediction, many patients are over-treated, effectively wasting limited resources and negatively impacting outcomes. Conversely, other patients may receive inadequate treatment, restricting options to only the most costly and least desirable interventions. Watch this on-demand webinar with Dr. Navdeep Tangri, developer of the Kidney Failure Risk Equation, which revolutionizes the way CKD patients are managed by leveraging laboratory data to accurately predict the risk of kidney failure in patients with CKD. You’ll learn: • How CKD is burdening our healthcare system, and the need for better care management tools • How the Kidney Failure Risk Equation was researched, developed, and validated • How Viewics is implementing CKD predictive analytics to automatically deliver risk information to clinicians and issue customized, educational reports to patients and clinicians

Rare Disease Drug Development Solutions Info Sheet

Covance

PCORI: Engaging Patients in Clinical Trials & Outcomes Research

National Alopecia Areata Foundation

The role of patients and healthcare providers in translational medicine

jangeissler

Reports indicate that 30 – 70% of blood transfusions are inappropriate. Inappropriate blood transfusions put patients at increased risk of post-surgical infections, multi-system organ failure, longer hospital stays, and higher mortality rates. The transfusion guidelines most clinicians learned in their training are now outdated. As such, blood transfusion practices vary widely, and overutilization remains a major quality and cost problem. Patient Blood Management (PBM) programs are designed to optimize the use of transfusions through a team-based approach, evidence-based guidelines, and algorithms that together guide decisions regarding specifically which patients and clinical procedures warrant blood products, and how much to transfuse. PBM programs have been quite successful in improving patient morbidity and mortality outcomes and generating millions of dollars in savings for hospitals. Laboratory analytics can be an effective means of instituting restrictive transfusion programs, and advanced lab analytics can be critical in implementing PBM programs, as lab testing and tracking blood usage is central to decision making, changing behavior, and improving performance. Watch a presentation by Dr. Eleanor Herriman, Chief Medical Informatics Officer at Viewics. She unveils a new suite of advanced analytics tools that support PBS and other restrictive blood management programs, enabling health systems to better leverage their valuable lab medicine assets and fully integrate this key service line into these programs. You’ll learn: • How inappropriate blood transfusions are burdening our healthcare system, and the need for better utilization management tools • New guidelines restricting red blood cell transfusions • The role of advanced lab analytics in PBM programs • How Viewics is leveraging advanced lab analytics to help health systems more easily and cost-effectively implement PBM programs

Advanced Laboratory Analytics — A Disruptive Solution for Health Systems

Viewics

As US healthcare systems grapple with the recent upheavals in care payment and delivery, they are turning to advanced analytics as their “central nervous systems” for driving care and financial performance. Laboratory information — spanning chemistry, pathology, microbiology and molecular testing, for example — is among the best sources of data for these advanced analytics, including clinician decision support, predictive analytics, population health management, and personalized medicine. When strategically harnessed and integrated to create a patient-centric lab data lake, laboratory information can form an affordable yet competitively powerful advanced analytics solution well suited for many health systems — i.e., a disruptive option. L. Eleanor J. Herriman, MD, MBA, Chief Medical Informatics Officer of Viewics, explains why laboratory data should be a core strategic component for achieving success in value-based healthcare.

Canada's path forward for rare diseases: Discovery to translation

Canadian Organization for Rare Disorders

Dr Colin Gaynor - Project managers as truth seekers - it's in our DNA

Association for Project Management

MT115 Precision Medicine: Integrating genomics to enable better patient outcomes

Dell EMC World

"The emergence of genomics and real-time screening is helping to transform the practice of medicine as we know it today. New technologies present improved ways to tackle health issues and what was once thought to be “untouchable” due to cost, timing or resources, is now achievable through genetic screenings and genome sequencing. During this session, we will explore: 1. The benefits of incorporating a genomics strategy early in lifeline 2. The Precision Medicine Initiative – how does this help? Does this encourage more people to get genetic screenings? 3. What’s involved in a genetic screening "

Kym Boycott, CHEO Diagnostic Breakthroughs: From Newborn Screening to Next Ge...

Canadian Organization for Rare Disorders

Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivo...

Cancer Institute NSW

Emergency Medicine Residency Applicant Assessment of Competitiveness and Appl...

Zach Jarou

Duke Industry Statistics Symposium - Real world evidence , EHRs and Cancer S...

Warren Kibbe

The Business of Genomic Testing by James Crawford

Knome_Inc

View this webinar at: http://www.knome.com/webinar-business-of-genomic-testing. This presentation discusses the findings of a College of American Pathologists survey of “early adopters” of NGS recently published in "Genetics in Medicine". The study objective was to identify the reasons for health systems to bring next-generation sequencing into their clinical laboratories and to understand the process by which such decisions were made. A standardized open-ended interview was conducted with the laboratory medical directors and/or department of pathology chairs of 13 different academic institutions in 10 different states.

Novellus DX

Health and Care Innovation Expo

Seventh Annual Next Generation Dx Summit

Jaime Hodges

The Next Generation Dx Summit (www.nextgenerationdx.com), entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement. With widespread coverage of all the most relevant diagnostics topics, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.

Health economic modelling in bowel cancerScHARR HEDS

Precision Medicine - The Future of Healthcare

Data Science Thailand

How Advanced Therapies are Changing the Landscape of Rare Disease

Medpace

Health economic modelling in the diagnostics development process

cheweb1

The referral process as imagined versus the referral process as done: co-deve...

Cancer Institute NSW

Genetics & Genomic Testing

CHC Connecticut

Big data sharing

Warren Kibbe

Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...

Medpace

WS3_Marsden_Filling in the Gaps edited.pdf

ssuser3372de

Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...

Canadian Organization for Rare Disorders

What's hot

Advanced Lab Analytics for Patient Blood Management Programs

Viewics

Advanced Laboratory Analytics — A Disruptive Solution for Health Systems

Viewics

Canada's path forward for rare diseases: Discovery to translation

Canadian Organization for Rare Disorders

Dr Colin Gaynor - Project managers as truth seekers - it's in our DNA

Association for Project Management

MT115 Precision Medicine: Integrating genomics to enable better patient outcomes

Dell EMC World

Kym Boycott, CHEO Diagnostic Breakthroughs: From Newborn Screening to Next Ge...

Canadian Organization for Rare Disorders

Secondary Cancers, Health Behaviour and Cancer Screening Adherence in survivo...

Cancer Institute NSW

Emergency Medicine Residency Applicant Assessment of Competitiveness and Appl...

Zach Jarou

Duke Industry Statistics Symposium - Real world evidence , EHRs and Cancer S...

Warren Kibbe

The Business of Genomic Testing by James Crawford

Knome_Inc

Novellus DX

Health and Care Innovation Expo

Seventh Annual Next Generation Dx Summit

Jaime Hodges

Health economic modelling in bowel cancerScHARR HEDS

Precision Medicine - The Future of Healthcare

Data Science Thailand

How Advanced Therapies are Changing the Landscape of Rare Disease

Medpace

Health economic modelling in the diagnostics development process

cheweb1

The referral process as imagined versus the referral process as done: co-deve...

Cancer Institute NSW

Genetics & Genomic Testing

CHC Connecticut

Big data sharing

Warren Kibbe

Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...

Medpace

What's hot (20)